Exencial Wealth Advisors’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Exencial Wealth Advisors’s Portfolio UBIO Stock Details UBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,125	Closed	-$209K	–	234
2019 Q1	$209K	Buy	+7,125	New	+$202K	0.05%	216

Other funds holding UBIO

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Exencial Wealth Advisors's UBIO Position: Q2 2019 in Review

Exencial Wealth Advisors sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q2 2019, closing a stake of 7,125 shares — an estimated $209K sold.

Exencial Wealth Advisors first reported a position in UBIO in Q1 2019 and held it in 1 quarter. The position peaked at $209K in Q1 2019. 6 funds tracked by Wall St. Rank hold UBIO as of Q2 2019.

Exencial Wealth Advisors reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q2 2019 after selling out during the quarter.
Exencial Wealth Advisors sold 7,125 Proshares UltraPro NASDAQ Biotechnology shares in Q2 2019, an estimated $209K.
Exencial Wealth Advisors first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q1 2019 and held it in 1 quarter.
Exencial Wealth Advisors's Proshares UltraPro NASDAQ Biotechnology position peaked at $209K in Q1 2019.
6 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q2 2019.

Based on Exencial Wealth Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.